NL-OMON30464尚未招募4 期
A randomised, double blind, parallel-group study of the oxidative stress lowering effect of simvastatin and atorvastatin. - The oxidative stress lowering effects of statins
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients in the age between 18 and 70 years, with diabetes mellitus type 2 and/or hypertension (RR > 140/90 mmHg) and/or obesity (BMI >25) and LDL > 2,5 mmol/l.
排除标准
- •Stage 5 chronic kidney disease
- •Use of an ACE inhibitor
- •Statin use in three months prior to inclusion
- •LDL cholesterol < 2,5 mmol/L
研究者
相似试验
已完成
4 期
A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners* sexual quality of life. PARTNER II.impotence10013356NL-OMON29704Bayer80
进行中（未招募）
1 期
A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II - PARTNER IIMales with Erectile DysfunctionEUCTR2006-001228-37-BEBayer HealthCare AG, D-51368 Leverkusen
进行中（未招募）
不适用
A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II - PARTNER IIMales with Erectile DysfunctionMedDRA version: 8.1Level: LLTClassification code 10061461Term: Erectile dysfunctionEUCTR2006-001228-37-DEBayer HealthCare AG, D-51368 Leverkusen308
进行中（未招募）
1 期
A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II - PARTNER IIEUCTR2006-001228-37-NLBayer HealthCare AG, D-51368 Leverkusen
进行中（未招募）
不适用
A global study to investigate the safety and effect on clinical outcome of tocilizumab given subcutaneously versus tocilizumab given intravenously, in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2010-018375-22-BGF. Hoffmann-La Roche Ltd1,200